trial

In: Finance

Sundry Photography/iStock Editorial via Getty Images Prelude Therapeutics (NASDAQ:PRLD) has forged a deal with Merck (NYSE:MRK) to test its investigational SMARCA2 degrader in combination with the latter’s blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with SMARCA4-mutated cancers. Shares of Prelude Therapeutics (PRLD) climbed as much as 28% following the news.Continue Reading

In: Finance

Michael Vi/iStock Editorial via Getty Images Biotechs developing a class of novel cancer drugs called anti-TIGIT therapies turned lower in the premarket Friday after a similar drug developed by Roche (OTCQX:RHHBY) failed in a Phase 2/3 clinical trial. Roche (OTCQX:RHHBY) shares fell in European trading on Thursday after the SwissContinue Reading

In: Finance

Andrii Dodonov Update 2.00PM EST: Adds latest share move and Oppenheimer’s downgrade Cell therapy developer Cartesian Therapeutics (NASDAQ:RNAC) announced Tuesday that its lead asset, Descartes-08, reached the main goal in a mid-stage trial against the muscle disorder myasthenia gravis (MG). In conjunction with the data, the Gaithersburg, Maryland-based biotech announcedContinue Reading

In: Finance

MicroStockHub X4 Pharmaceuticals (NASDAQ:XFOR) traded sharply lower on Thursday after the biotech updated data from an ongoing Phase 2 trial for its lead candidate mavorixafor in chronic neutropenia (CN), a rare blood disorder. Citing a May 24 data cut, the Boston, Massachusetts-based biotech said mavorixafor, which X4 (XFOR) markets asContinue Reading

In: Finance

Sundry Photography/iStock Editorial via Getty Images Johnson & Johnson (NYSE:JNJ) has discontinued a Phase 2 trial for its blockbuster arthritis therapy Tremfya in patients with an autoimmune disorder called giant cell arteritis after the study failed to meet the primary goal, according to updated data from a federal register ofContinue Reading

In: Finance

Anne Czichos Shares of Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY) fell in European trading on Tuesday after the German drugmaker said it would discontinue a late-stage trial for its head and neck cancer therapy xevinapant as its early results indicated a potential failure. The decision comes after the study’s data monitoring committeeContinue Reading

In: Finance

jetcityimage/iStock Editorial via Getty Images AstraZeneca (NASDAQ:AZN) announced Tuesday that its blockbuster immunotherapy Imfinzi failed in a late-stage trial for patients with early-stage non-small cell lung cancer whose tumors have been surgically removed. Citing data from a Phase 3 trial called ADJUVANT BR.31, the company said Imfinzi did not demonstrateContinue Reading